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Previously, VLPs bearing JR-FL strain HIV-1 Envelope trimers elicited potent neutralizing antibodies (nAbs) in 2/8 rab-
bits (PLoS Pathog 11(5): e1004932) by taking advantage of a naturally absent glycan at position 197 that borders the
CD4 binding site (CD4bs). In new immunizations, we attempted to improve nAb responses by removing the N362 gly-
can that also lines the CD4bs. All 4 rabbits developed nAbs. One targeted the N197 glycan hole like our previous sera.
Two sera depended on the N463 glycan, again suggesting CD4bs overlap. Heterologous boosts appeared to reduce nAb
clashes with the N362 glycan. The fourth serum targeted a N362 glycan-sensitive epitope. VLP manufacture challenges
prevented us from immunizing larger rabbit numbers to empower a robust statistical analysis. Nevertheless, trends sug-
gest that targeted glycan removal may improve nAb induction by exposing new epitopes and that it may be possible to
modify nAb speciUcity using rational heterologous boosts.
1. Introduction
Eliciting broadly neutralizing antibodies (bnAbs) is a major goal of
HIV-1 vaccine development. NAbs block infection by binding to na-
tive envelope glycoprotein (Env) spikes on virus surfaces, thereby pre-
venting transmission (Burton and Hangartner, 2016). The compact, se-
quence-diverse, and heavily glycosylated nature of these spikes allows
the virus to largely evade neutralization (Kwong and Mascola, 2012;
Pancera et al., 2014). Nevertheless, a growing number of monoclonal
antibodies (mAbs) have been isolated from HIV-infected individuals
that can potently and broadly neutralize tier 2 strains (Burton and
Hangartner, 2016). These bnAbs can protect animal models against vi-
ral challenge (Shingai et al., 2014), suggesting that if sufUcient titers of
similar bnAbs can be induced by vaccination, they could prevent HIV
infection.
Autologous nAbs typically develop within a few months during
natural infection, and invariably precede any breadth development.
The appearance of bnAbs is frequently associated with increased vi-
ral diversity as the virus
escapes autologous nAbs, often by the acquisition of new glycans
(Bhiman et al., 2015; Liao et al., 2013; Moore et al., 2012, 2009;
Murphy et al., 2013; Wibmer et al., 2013). A logical vaccine strategy is
to mimic the bnAb development processes observed in natural infection
by Urst developing a platform to consistently elicit potent autologous
tier 2 nAbs as a foundation, then using heterologous boosts to broaden
nAb cross-reactivity to shared epitopes (Derdeyn et al., 2014; Moore et
al., 2012; Ping et al., 2013; Wibmer et al., 2013).
Until recently, most vaccine candidates largely elicited weak or
undetectable autologous tier 2 nAbs, let alone any breadth (Burton
and Hangartner, 2016). This may be because these vaccine candidates
insufUciently resemble native spikes and consequently elicit largely
oX target responses. These problems have, to some extent, been re-
cently solved by the development of "near native" soluble SOSIP gp140
trimers that can elicit potent autologous nAbs in most vaccinated rab-
bits (Cheng et al., 2015; de Taeye et al., 2015; Sanders et al., 2015).
However, remaining challenges include the order of magnitude dif-
ferences in nAb titers among immunized rabbits, the markedly dif-
fering propensities of SOSIP trimers prepared from
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different strains to induce nAbs and the relatively modest nAb titers
in vaccinated non-human primates (NHPs). The helix breaking I559P
mutation and/or the lack of a natural, membrane setting could also be
problematic. The reduction in VRC01 and PGT151 bnAb recognition
caused by the I559P mutation (AlsahaU et al., 2015) suggests a con-
formational impact. Furthermore, Env ectodomain conformation differs
when expressed in situ with transmembrane and cytoplasmic domains
(Abrahamyan et al., 2005; Chen et al., 2015; Montero et al., 2012).
Thus, although all BG505 SOSIP.664 gp140 trimers-vaccinated animals
may generate potent binding titers, not all may cross react with native
membrane-expressed trimers and neutralize (Hu et al., 2015). This prob-
lem could be exacerbated in NHPs where a more sophisticated antibody
repertoire may generate antibodies that can better distinguish the mod-
est differences between SOSIP trimers and their native membrane coun-
terparts.
Considering the above concerns, it is reasonable to pursue vaccine
strategies in which Env trimers are presented in a native, membrane set-
ting. To this end, we have been developing virus-like particles (VLPs)
(Crooks et al., 2007, 2015; Tong et al., 2014). We previously suggested
that non-functional Env present on VLP surfaces may interfere with their
ability to induce nAbs (Tong et al., 2014). To address this problem, we
showed that a protease blast can selectively remove non-functional Env
from VLP surfaces, leaving trimers intact (Crooks et al., 2011; Tong et
al., 2012). Immunizations with high doses of the resulting "trimer VLPs"
induced remarkably potent serum nAbs in 2 out of 8 rabbits that tar-
geted a strain-speciUc hole in the trimer's carbohydrate shell left by the
natural absence of the N197 glycan in the C2 domain of JR-FL gp120
(Crooks et al., 2015). These sera neutralized other clade B tier 2 isolates
when the N197 glycan was removed, suggesting that they target a con-
served site to which access is usually regulated by a glycan.
In a more recent study, strain-speciUc glycan holes were also found
to be targeted by autologous nAbs in rabbits immunized with BG505
SOSIP.664 gp140 trimers (McCoy et al., 2016). Similar glycan holes are
also frequently targeted by autologous nAbs during natural infection
(Derdeyn et al., 2014; Moore et al., 2012, 2009; Wibmer et al., 2016).
These Undings are in line with known antibody preference for binding
protein over glycan, with the latter speciUcities being largely eliminated
from the repertoire at tolerance checkpoints (Haynes et al., 2012). The
carbohydrate shell encasing native Env trimers (Julien et al., 2013; Lee
et al., 2016; Lyumkis et al., 2013; Pancera et al., 2014; Stewart-Jones et
al., 2016) appears to dampen germline antibody triggering (McGuire et
al., 2014, 2013; Ota et al., 2012; Ping et al., 2013; Zhou et al., 2010).
Nevertheless, bnAbs targeting the V2 apex, V3-glycan and gp120/gp41
interface epitope clusters make protein and glycan contacts (McLellan
et al., 2011; Pejchal et al., 2011; Walker et al., 2011, 2009). In contrast,
bnAbs targeting the CD4 binding site (CD4bs) (Burton and Hangartner,
2016) largely contact protein epitopes, but must also either avoid or
make contacts with glycans that line the CD4bs (Huang et al., 2016;
Pancera et al., 2014; Stewart-Jones et al., 2016).
The fence of glycans lining the CD4bs has evolved to leave a gap
sufUcient to accommodate the single immunoglobulin-like domain of
CD4 but insufUcient to grant easy access to a pair of immunoglobulin
domains, i.e. antibody heavy and light chains (Heydarchi et al., 2016;
McCoy et al., 2012). Despite this problem, the CD4bs remains an attrac-
tive vaccine target in part due to the many paradigms provided by mon-
oclonal antibodies (mAbs) recovered from naturally infected donors.
These include germline-encoded speciUcities like that of the VRC01
mAb, in which binding is dominated by the HCDR2 domain, and those
in which binding is dominated by a long CDRH3 domain (Huang et al.,
2016; Kwong and Mascola, 2012; Stewart-Jones et al., 2016; Zhou et al.,
2010, 2015).
Here, we tried to improve the frequency of nAb responses to JR-FL
trimer VLPs by enlarging the CD4bs glycan hole. We found that 4
out of 4 animals (100%) developed autologous nAbs, in contrast to
25% in our previous study (Crooks et al., 2015) - a difference that
appeared to stem from the exposure of new epitopes by removing
the N362 glycan. Boosting with VLPs in which the N362 glycan was
reinstated appeared to enable sera to navigate past this glycan and
neutralize the parent virus. In a second study,
plasmid DNA expressing VLP components appeared augment nAb induc-
tion by VLP protein immunogens. Although our VLP production chal-
lenges precluded a larger analysis that would be needed for full statis-
tical powering, our data provide some leads that might beneUt vaccine
development.
2. Results
2.1. An enlarged glycan hole improves trimer access to CD4 binding site
mAbs
Our previous immunogenicity studies suggested that VLP efUcacy
may be improved by i) eliminating antigenic interference by non-func-
tional Env, ii) by using higher VLP doses and iii) by using rabbit mod-
els (Crooks et al., 2015; Tong et al., 2014). So far, at best, potent tier
2 nAbs developed in only 25% of rabbits, suggesting a need for further
improvements (Crooks et al., 2015). These sera targeted the space va-
cated by the naturally absent N197 glycan on the JR-FL vaccine strain,
situated adjacent to the CD4bs. Fig. 1A shows the fence of glycans (ma-
genta) through which antibodies must navigate to contact the underly-
ing CD4bs protein site (yellow). MAb VRC01 docking (Fig. 1B) reveals
how this ligand must exquisitely circumnavigate this fence to contact
underlying protein.
In the JR-FL strain, the fence occurs at positions N276, N362, N386,
N392 and N463 (Fig. 1A). The precise positioning of fence glycans dif-
fers between strains. Indeed, one or more fence glycans may be miss-
ing in some strains (as for the N197 glycan of the JR-FL strain). In this
case, partial masking of underlying protein may still be achieved by re-
arrangement of the interlocking network of remaining glycans to par-
tially Ull the vacated space (Gristick et al., 2016; Stewart-Jones et al.,
2016; Zhou et al., submitted for publication). The remaining glycans
may also undergo more complex differentiation, adding mass to par-
tially Ull glycan holes (Behrens et al., 2016). Indeed, despite being a nAb
target in our previous study (Crooks et al., 2015), the N197 glycan hole
was only targeted by 2 out of 8 animals, suggests that is only partially
accessible.
In this follow up study, we reasoned that enlarging the glycan-free
CD4bs hole by removing another glycan (in addition to the already ab-
sent N197 glycan) might improve nAb induction. To inform our selec-
tion of a glycan knockout mutant, we Urst analyzed the effects of knock-
ing out each of the 5 JR-FL strain fence glycans on JR-FL E168K mu-
tant virus sensitivity to mAb VRC01. The E168K mutant was previously
used to partially knock in V2 apex bnAb sensitivity and fortuitously im-
proves trimer expression. The VRC01 mAb was selected to character-
ize these mutants because it exhibits a germline-encoded CDRH2-dom-
inated binding mode that is almost exactly replicated by other "VRC01
class" bnAbs isolated from other donors, thus making it a useful pro-
totype for vaccine researchers (Kwong and Mascola, 2012; Zhou et al.,
submitted for publication; Zhou et al., 2010; Zhou et al., 2015; Zhou
et al., 2013). The N276A and N362Q mutants were approximately 3-
and 8-fold more VRC01-sensitive than the parent, respectively (Fig. 1D),
whereas N386, N392 and N463 knockout mutants all had little or no
effect. Conversely, a glycan knock-in at position 197 markedly reduced
VRC01 sensitivity (Fig. 1D). We previously observed that this mutation
reduces mAb b12 sensitivity by ~100-fold, demonstrating its key role in
regulating CD4bs nAb access (Crooks et al., 2015).
Based on the above Undings, we selected the N362Q mutant for
follow up (Fig. 1C). In further neutralization assays, we examined the
effects of this mutant on sensitivity to other mAbs. MAb 8ANC131,
which also employs a CDRH2-dominated binding interface but encoded
by a different germline (Zhou et al., 2015) was also 2-fold more po-
tent on the N362Q mutant. MAb b12, that uses a long CDRH3-domi-
nated CD4bs binding mode, neutralized the N362Q mutant with simi-
lar potency to the parent virus (Fig. 1E). As mentioned above, b12 sen-
sitivity is instead heavily regulated by the N197 glycan. VRC13, an-
other CDRH3-dominated prototype mAb, was 2 3-fold more effective
against the mutant. A broadly neutralizing HIV-positive donor serum
(1688) that targets the CD4bs was 3-fold more potent on the mutant,
whereas little change was noted in sensitivity to a serum that targets
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Fig. 1. N362 glycan removal improves antibody access to the CD4 binding site. A) The ectodomain of native, full-length cleaved JR-FL Env trimers in pdb 5FUU (Lee et al., 2016) is shown
in side and top views. Gp41 is shown in grey and gp120 protomers are shown in different shades of green. The CD4 binding loop (residues 360 370) and putative CD4 contact positions
427 and 477 are shaded yellow. Since complex glycans may exhibit branches that are difUcult to predict and/or unequivocally model (Bonomelli et al., 2011), all glycans were modeled as
Man⁠8GlcNAc⁠2. Those that form a fence around the CD4bs are colored in magenta. Residue 197 is colored in red. This position bears a glycan in most strains that forms part of the glycan
fence, but is naturally absent in the JR-FL strain. Close glycan spacing may limit their differentiation, presumably by limiting access to glycan processing enzymes (Behrens et al., 2016;
Stewart-Jones et al., 2016; Zhou et al., 2013). However, since a carbohydrate-free gap is necessary to admit CD4 binding, it is logical that some of the surrounding glycans are relatively
well differentiated (Behrens et al., 2016). Since complex glycans usually have a greater mass than Man⁠8GlcNAc⁠2, the CD4bs is probably even better protected than shown here. Glycans
were added to all NXS/T sequons except for N189 and N637. Due steric clashes with glycans at proximal sites, these sites may not be occupied. Furthermore, regions of structural disorder
in the C1, V1 and V4 and any associated glycans (see Fig. S1) are not shown. B) Fab VRC01 (3NGB), rendered in aqua ribbon format, is docked onto the trimer. C) The N362 glycan is
removed, as in our JR-FL N362Q mutant vaccine strain and the underlying residue is colored red. D) Sensitivity of JR-FL glycan fence mutants to VRC01 neutralization. E) Sensitivity of
the JR-FL SOS E168K parent and N362Q mutants to various mAbs. F) Binding of mAbs VRC01 and 2G12 to VLPs bearing the same Env trimers by ELISA.
the gp41 membrane proximal ectodomain region (MPER) (Fig. 1E;
(Binley et al., 2008)). MAbs HJ16 and 179NC75, both of which depend
on the N276 glycan, were unable to neutralize either the parent or the
mutant virus (Fig. 1E and not shown). The neutralizing activities of var-
ious other mAbs were essentially unchanged (Fig. 1E). Non-neutralizing
mAbs 15e and CO11, directed to CD4bs and V3 epitopes, respectively,
did not neutralize either the parent or the N362Q mutant, suggesting
that the mutant did not overtly impact trimer conformation. PG16 did
not reach an IC50 against this virus at the concentrations tested, as
full sensitivity requires an additional N189A mutation of this strain to
eliminate a competing glycosylation site (Doores and Burton, 2010).
VLP ELISAs mirrored the neutralization data: VRC01 bound the mutant
10-fold better than the parent VLPs, whereas 2G12 bound both VLPs
equivalently (Fig. 1F). Collectively, this data shows that the N362Q mu-
tant is more sensitive to the VRC01 mAb and certain other CD4bs mAb
and was therefore selected for immunization studies to test whether a
larger glycan hole might improve nAb induction.
2.2. EBects of an enlarged glycan hole on immunogenicity
Fig. 2 provides an overview of Study 1. The "SOS" mutant was
used to introduce a gp120-gp41 disulUde bond (Binley et al., 2000)
and also improves trimer expression compared to the non-mutated
wild type (WT)
Fig. 2. Overview of rabbit immunizations. 4 rabbits were immunized with N362Q trimer
VLPs and were later boosted with a mixture of these VLPs with parent VLPs (N362 glycan
intact). VLPs were produced in 293 T cells and were formulated in AS01⁠B. The day of each
immunization is indicated along with bleeds (B1-B5), taken two weeks thereafter.
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trimer (Crooks et al., 2005; Moore et al., 2006). We previously showed
that E168K, SOS mutations and gp41 tail truncation all have only mar-
ginal effects on neutralization sensitivity, justifying their use as im-
munogens (Crooks et al., 2005). VLPs were produced by co-expression
of Env, ERV (MuLV) Gag and HIV-1 Rev plasmids. MuLV Gag modestly
improved VLP Env trimer yield, as compared to SIV-derived p55 Gag
used previously (Crooks et al., 2015).
Prior to immunizations, VLPs were treated with proteases to sub-
stantially remove non-functional Env, leaving native Env trimers intact,
resulting in trimer VLPs (Crooks et al., 2011; Tong et al., 2012). We
immunized a group of 4 rabbits, starting with 4 shots of N362Q mu-
tant trimer VLPs (our index immunogen) at 0, 1, 3 and 6 months. VLP
doses were high and matched those used in our previous study (~150 g
gp120 equivalents/kg) (Crooks et al., 2015). None of the VLP-immu-
nized animals exhibited any clear ill effects or toxicity related to immu-
nizations. However, rabbit 742 died unexpectedly 168 days after the 4th
shot for reasons that did not appear to be related to immunizations. The
3 surviving animals were later boosted with parent VLPs (Fig. 2) to try
to train rabbit nAbs to navigate the N362 glycan. This was mixed with
smaller dose of the N362Q index immunogen to ensure the reactivation
of nAb memory B cell clones primed by the preceding 4 N362Q VLP
shots.
We did not immunize a concurrent control group with parent trimer
VLPs because the high VLP doses needed to induce nAbs that we re-
ported in our previous studies require significant labor to produce
(Crooks et al., 2015; Tong et al., 2014). Indeed, we estimate that, using
equivalent expression systems, per unit time, >100-fold more doses of
SOSIP trimer can be produced compared to VLPs. This may relate to the
relative inefUciency of multi-plasmid transfection, low Env spike density
on VLP surfaces and the relatively constrained (i.e. less immunogenic)
Env conformation in a membrane setting, that collectively mandate high
VLP doses. Therefore, we decided to bridge the current immunized rab-
bits to the rabbits we previously immunized with parent trimer VLPs
(termed reference groups A and B). The latter received equivalent high
VLP doses as in the new study, were administered in the same adjuvant
and were analyzed in the same way.
A proUle of peak sera from the new rabbits along with reference sera
is shown in Fig. 3. "Peak" time points are those with the highest neu-
tralizing ID50 against either the JR-FL parent or N362Q virus (a kinetic
analysis of nAb development follows below). The bleed numbers shown
(i.e. B3, B4 and B5) correspond to those depicted in Fig. 2. Data for
bleed 4 sera from reference groups A and B is shown except for rabbit
347 that died before the 4th shot (Crooks et al., 2015). We also included
plasmas from an HIV-1 donor (1702) and an uninfected human control
(210) (Binley et al., 2008; Crooks et al., 2005).
Serum titers to parent JR-FL gp120 monomer (i.e. carrying the N362
glycan) are shown as green circles in Fig. 3A. Gp120 titers ranged from
1:1520-1:54,192 (Crooks et al., 2015). Titers between groups were com-
pared by Mann-Whitney tests. Reference group B titers were not sig-
nificantly higher than those in group B (P=0.0571). However, Study 1
titers were significantly higher than those in group A (P=0.0286) but
were not higher than those in group B (P=0.4857). Overall, despite the
presence of the N362 glycan on the gp120 monomer antigen used in
these assays, the new rabbit sera exhibited equivalent or better titers
than previous sera but they were weaker than human plasma 1702 (al-
though the need for different conjugates precludes a formal comparison
of the latter).
Serum titers to bald VLPs are shown as blue triangles in Fig. 3A.
High titers were observed in all Study 1 animals. Differences between
groups A and B were not significantly different (P=0.2), nor were they
for Study 1 and group A (P=0.6857). However, Study 1 titers were sig-
nificantly higher than those in group B (P=0.0286). Again, this data
supports the equivalent or better immunogenicity of the new VLP im-
munogens. The apparently high bald VLP titer also observed in plasma
1702 may in part be explained by lipid-reactive antibodies that are be-
nign and ubiquitous in nature (Alving, 2008; Tong et al., 2014).
Fig. 3. Study 1 serum binding and neutralization proUles. Peak time points for each
N362Q trimer VLP-immunized rabbits were compared with two groups of 4 sera from
our previous
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study, termed here as reference groups A and B (Crooks et al., 2015), along with human
HIV-1-seropositive (1702) and uninfected (210) human control plasmas. A) ELISA titers
against recombinant JR-FL gp120 monomer and bald-VLPs. Data are means of at least two
repeats. Neutralizing activity against B) the tier 1 phenotype mutant JR-FL WT A328G
(Tong et al., 2014) and SIVmac239, and C) the JR-FL SOS E168K+N362Q index strain
and parent JR-FL SOS E168K measured in CF2Th. CD4. CCR5 cells. All neutralization as-
says were performed at least three times in duplicate. Mean ID50s and standard deviations
are shown. P values for Mann-Whitney tests are shown only when there were significant
differences (i.e. <0.05) between groups. For these tests, undetectable <1:4 neutralizing
ID50s were assigned as 1:4.
Serum neutralization was assessed using CF2 target cells (Crooks et
al., 2015; Tong et al., 2014). The JR-FL A328G mutant (Tong et al.,
2014) was used to assay tier 1 nAbs, shown as magenta diamonds in
Fig. 3B. This mutant causes a folding defect that results in V3 loop ex-
posure, similar to some other reported Env mutants (Blish et al., 2008)
and can therefore detect "oX target" tier 1 nAbs that matches the JR-FL
vaccine strain Env sequence. Titers in groups A and B were compara-
ble (P=0.7429), as were those of group A and Study 1 (P=0.2286) and
group B and study 1 (P=0.3429). As expected, none of the sera neutral-
ized the control virus SIVmac239 (black triangles in Fig. 3B).
Unlike the reference groups, all Study 1 rabbits developed nAbs
to the tier 2 index N362Q virus (orange triangles in Fig. 3C). By
Mann-Whiney test, there were no differences between groups A and B
(P>0.99). Neither were there significant differences between Study 1
sera and the two reference groups (P=0.2 in both cases). The difference
between Study 1 sera and groups A and B combined was also not quite
significant (P=0.0687).
Three Study 1 sera also neutralized the parent virus (red circles in
Fig. 3C). Sera 740 and 742 titers were comparable to sera 347 and 613.
As for the N362 titers, there was no difference in parent virus nAb re-
sponses by groups A and B. The differences between Study 1 and each
of groups A and B were not significant (P=0.4857 and 0.3714, respec-
tively) and were also not significant when groups A and B were com-
bined (P=0.2788). Overall, although a trend that suggests positive nAb
responses in the new N362Q VLP-immunized rabbits, the group differ-
ences did not reach statistical significance. It should be emphasized that
until recently, most vaccine sera have failed to generate any detectable
autologous tier 2 nAb responses, as exempliUed by sera 611, 612, 614,
345, 346 and 348 of the control groups A and B (Fig. 3C) (Sanders et
al., 2015).
Three Study 1 sera neutralized the N362Q index virus more effec-
tively than the JR-FL parent, whereas serum 742 neutralized the par-
ent marginally more effectively (Fig. 3C). We next analyzed neutralizing
ID50 kinetics over the course of immunizations (Fig. 4). To detect subtle
changes, we used 4 JR-FL mutants: WT parent, SOS parent, WT N362Q
and SOS N362Q (Fig. 4). Rabbits 740 and 741 both exhibited an early
strong preference for SOS N362Q, matching the immunogen, at bleeds 3
and 4. However, this changed dramatically after rabbit 740 was boosted
with a mixture of parent and N362Q VLPs, whereupon it gained an abil-
ity to neutralize all 4 variants equally. Similar mixed boosting of rab-
bit 741 also led to an increase in neutralization against the SOS parent
virus, with a concomitant lowering of titers against the two N362Q mu-
tants (Fig. 4).
Serum 742 exhibited strong initial titers, particularly to SOS mutant
viruses (regardless of N362Q mutation) at bleed 3, and had lower titers
against the respective WT versions of these viruses. Upon further boost-
ing, titers against these N362Q viruses improved while those against
parent viruses dropped. Thus, it appears that repeated boosting led to
increased N362 glycan sensitivity. Nevertheless, the general ability of
this serum to neutralize all variants effectively suggests a conserved epi-
tope. Unfortunately, this animal died before heterologous boosting.
Serum 743 developed nAbs against the N362Q index immunogen at
bleed 5. This was somewhat surprising, considering that the preceding
boost predominantly consisted of parent VLPs (Fig. 4). We infer that
serum 743 overlaps the protein surface revealed by the missing N362
glycan, otherwise referred to as a N362 glycan-sensitive.
Fig. 4. Longitudinal analysis of neutralizing responses in vaccinated rabbits. Changes in
serum ID50 titers against four JR-FL variants were followed over the course of immuniza-
tion of all 4 Study 1 rabbits that generated tier 2 nAbs. The four variants analyzed were
JR-FL WT (open symbols) and SOS versions (solid symbols) of the N362Q index (orange)
and parent (red) strains. The preceding immunogen boost for each bleed is indicated by
arrows. The color scheme matches that used in Figs. 2 and 3.
2.3. Potent nAbs recognize native trimers in a largely D368-independent
manner
We previously showed that neutralization correlates with antibody
binding to native trimers as measured in BN-PAGE-Western blot shifts
(Binley et al., 2008; Crooks et al., 2007, 2005; Moore et al., 2006;
Tong et al., 2012). Peak serum IgG (Fig. 3) from animals 740 743 of
Study 1 all bound to native SOS E168K+N362Q trimer, as evidenced
by depletion of the unliganded trimer (Fig 5A, upper panel). Serum
613 from reference group A also bound these trimers, as did mAbs
b12 and 2G12. Neutralizing IgG from rabbits 773 and 776 of Study
2 (described later below) also bound to trimers but non-neutralizing
serum IgG from rabbit 770 (also from Study 2) did not bind trimers.
Study 1 sera also bound SOS E168K trimers (Fig. 5A, middle panel).
Notably, although neutralization was not detected in Fig. 4, serum 743
IgG shifted this trimer, suggesting some weak activity. Serum IgG from
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Fig. 5. Serum binding to native trimers and quaternary epitope dependency. A) Antibody binding to the native Env trimer was assessed in BN-PAGE shift assays. BrieVy, mAbs b12
(3 g/ml) and 2G12 (30 g/ml) or protein A-puriUed IgG from rabbit serum peak bleeds (see Fig. 3) were incubated with JR-FL SOS E168K+N362Q, JR-FL SOS E168K, or JR-FL SOS
E168K+N362Q+D368R trimer VLPs, as indicated. VLPs were then washed and lysed, and Env was resolved by BN-PAGE-Western blot. As we observed previously, IgG-trimer complexes
were rarely visible (Tong et al., 2012), perhaps due to the formation of higher order complexes. In marked contrast, mAb 2G12 exhibits a ladder of bound trimer species owing to monova-
lent binding. B) The effect of adding 10 g/ml of puriUed N362Q+D368R JR-FL gp120 monomer on serum and mAb neutralization of JR-FL gp160 CT WT E168K and JR-FL gp160 CT
WT A328G is shown.
rabbits 740, 741, 743 and 613 all bound to triple mutant SOS
E168K+N362Q+D368R trimers (Fig. 5A, lower panel), consistent with
D368-independent trimer binding. Interestingly, rabbit 742 IgG failed
to fully deplete this mutant trimer, thus indicating some D368-depen-
dency. As expected, b12 binding was eliminated by the D368R muta-
tion, but 2G12 binding was retained.
2.4. Quaternary epitope dependency of serum neutralization
Interference neutralization assays in which monomeric gp120 is
pre-incubated with virus-serum mixtures can reveal whether sera target
epitopes that found on the gp120 monomer or, alternatively, may be ex-
clusively accessible on the native trimer. Above, we veriUed that all our
vaccine sera can bind to E168K+N362Q+D368R mutant trimers, al-
beit weakly for the 742 serum (Fig. 5A, lower panel). We therefore used
E168K+N362Q+D368R gp120 monomer in interference assays using
SOS E168K+N362Q and globally sensitive tier 1 phenotype WT A328G
viruses (Fig. 5B).
For rabbits 740 and 741, we examined bleed 4 and 5 sera to in-
vestigate any differences that might associate with those we observed
in Fig. 4. Neutralization of both viruses by bleed 4 of rabbit 740 was
highly gp120 sensitive (Fig. 5B). However, some gp120 monomer re-
sistance was acquired at bleed 5. Thus, following mixed VLP boosting,
nAbs became more gp120-resistant, suggesting quaternary epitope de-
pendency (i.e. exclusive trimer binding) while also gaining an ability
to cross-neutralize JR-FL variants. To a lesser extent, neutralization of
the A328G mutant virus also became gp120-resistant at bleed 5. Al-
though this tier 1 variant is expected to be neutralized predominantly
by V3 loop-speciUc antibodies that can be adsorbed by gp120, this sug-
gests that quaternary nAbs may also neutralize this variant. In contrast,
serum 741 neutralized all viruses in a gp120 monomer-sensitive man-
ner (Fig. 5B), perhaps reVecting the less dramatic changes observed in
Fig. 4. Neutralization by sera 742 and 743 was also largely sensitive to
gp120. The modest gp120-resistance of serum 742 neutralization of the
index virus may be explained by its modest D368R-sensitivity observed
in BN-PAGE shifts (Fig. 5A). As expected, gp120 adsorbed 2G12 activity.
Overall, although some sera (740 B5 and 742 B4) exhibited some
gp120-resistance, most vaccine sera targeted epitopes that were largely
contained within gp120. This contrasted with our previous study in
which sera were insensitive to gp120 (see Fig. S7 in (Crooks et al.,
2015)). As described below, this could reVect the somewhat different
epitopes targeted by the new sera.
2.5. Neutralizing sera target the CD4bs glycan hole
Study 1 rabbit sera failed to significantly neutralize other tier 2
viruses aside from the vaccine strain as has been consistently true all
HIV vaccine studies to date. This allowed us to map the 740, 741 and
742 sera by checking their activities against a panel of chimeric JR-FL
Env pseudoviruses with JR-CSF domain swaps (Narayan et al., 2013)
(Fig. 6). We did not map the 743 as it did not significantly neutralize the
JR-FL parent virus (Fig. 4). As we reported previously, most chimeras
were infectious and resistant to the V3 loop-speciUc mAb CO11 (Crooks
et al., 2015; Tong et al., 2014), suggesting that they retain a tier 2 phe-
notype. All chimeras bearing JR-CSF strain V5 domains were resistant
to the 740 and 741 sera. A V5 sequence comparison reveals a glycan
at positions 461 and 463 in the JR-CSF and JR-FL strains, respectively
(sequons are boxed in red in Fig. 7A). Further analysis revealed that
serum 740 neutralized a JR-CSF chimera with an engrafted JR-FL V5
region, but did not neutralize the JR-FL N463Q mutant (Fig. 7B). To-
gether, this suggests that the N463 glycan is either part of the serum
epitope or imparts a local conformational effect that is important for
recognition. For convenience, we henceforth term this N463 glycan-de-
pendent. Notably, the infectivities of all 740 serum resistant viruses
were nevertheless somewhat reduced (but did not reach an IC50; Fig.
7B). We speculate that serum 740 may recognize protein sequence com-
mon to these related variants, but requires the glycan to fully neu-
tralize. Incomplete neutralization is in fact a common feature of sev-
eral bnAbs (McCoy et al., 2015). Serum 741 also depended on the
N463 glycan (Fig. 7C). An analysis of 4265 Env sequences in the Los
Alamos HIV sequence database (www.hiv.lanl.gov) reveals that this gly-
can is ~20% conserved. However, the 740 serum did not cross-neu-
tralize 6 other strains that naturally carry a glycan at this position
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Fig. 6. Neutralization of JR-FL-JR-CSF chimeras. Chimeras comprising of a JR-FL Env background (violet) with JR-CSF domain swaps (salmon) were evaluated for infectivity (in relative
light units; RLU) and sensitivity to vaccine sera and mAb CO11 and b12 neutralization. N.D. denotes not done due to low infectivity.
Fig. 7. Fine mapping of the sera from rabbits 740 and 741. A) Alignment of the JR-FL and JR-CSF V5 sequences. Glycan sequons are boxed in red. B) Serum 740 (bleed 5) activity against
various JR-FL and JR-CSF viruses, including those carrying V4V5 or V5 domain swaps and a JR-FL N463Q knockout mutant. C) Serum 741 (bleed 5) activity against the JR-FL parent and
N463Q glycan knockout mutant. D) Serum 740 neutralization of various clade B viruses that carry a N463 glycan. E) Effect of glycan fence modiUcations on serum 740 neutralization.
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(Fig. 7D), perhaps due to sequence variation. Given that the N463 gly-
can is part the CD4bs fence (at least in the JR-FL strain), we wondered
if removing other fence glycans might impact virus sensitivity to serum
740 (or, in the case of D197N, knocking in a glycan). However, these
mutants had no impact (Fig. 7E).
We next investigated the effects of viral glycan modiUcation on sen-
sitivity to sera 740 and 741. Approximately 2/3 of the glycans on na-
tive trimers are of high mannose type and 1/3 are of complex type
(Bonomelli et al., 2011). Several lines of evidence suggest that the N463
glycan is complex in nature. First, previous studies of various forms of
Env derived from various strains have consistently described the glycan
at this position as being complex (Behrens et al., 2016; Go et al., 2008;
Leonard et al., 1990). Second, high mannose glycans tend to occur at
well-conserved gp120 positions (e.g. N156 and N276) and may there-
fore have a structural role in trimer folding. Thus, the relatively poor
conservation of the N463 glycan is in keeping with a complex glycan.
Third, the proximity of the N463 glycan to the CD4 binding site may
facilitate its processing and maturation (Behrens et al., 2016). Thus, as-
suming the N463 glycan is complex in JR-FL native trimers, we next
determined the effect of adding kifunensine during transfection on the
neutralization sensitivity. Kifunensine blocks -mannosidase I trimming,
thereby rendering all Env glycans as untrimmed high mannose type. Un-
expectedly, this significantly increased virus sensitivity to these sera but
had little effect on the 742 and 613 sera (Fig. 8). As expected, PG9 sen-
sitivity was knocked out by this treatment (Walker et al., 2011), while
mAb VRC01 was marginally more effective. This data is consistent with
the idea that the 740 and 741 sera recognize an epitope dependent on
the N463 glycan stem (or a structure inVuenced by it).
We next attempted to map serum 742 which neutralized all the
functional chimeras in Fig. 6. However, chimeras in which the JR-CSF
C2 region was substituted into the JR-FL background were not func-
tional ((Crooks et al., 2015), Fig. 6). We suspected that serum 742
might recognize a N197 glycan-sensitive epitope like that recognized
by the 347 and 613 sera (Crooks et al., 2015). The N197 glycan is
present in 98.7% of circulating strains (Crooks et al., 2015). Its ab-
sence in the JR-FL isolate is therefore highly unusual. To in
vestigate this idea, we examined the sensitivity of viruses with muta-
tions at this position to the 742 serum. A D197N glycan knock-in mutant
of the parent JR-FL strain was resistant (Fig. 9A). Reciprocally, a JR-CSF
N197D mutant was sensitive. This suggests that the N197 glycan reg-
ulates this serum (Fig. 9A). Further analysis of N197 glycan knockout
mutants revealed that serum 742 cross-neutralized N197D mutants of
the ADA isolate but no other clade B strains (Fig. 9A). Glycan fence mu-
tants revealed no other changes in neutralization sensitivity aside from
that at position 197 (Fig. 9B). Thus, the 742 serum exhibits modest tier
2 breadth within clade B by recognizing the conserved protein surface
protected by the N197 glycan. Notably, the identities of the N197 gly-
can-lacking viruses sensitive to the 742 serum were the same as those
that were sensitive to serum 347, and were among the larger number of
N197 glycan-lacking viruses sensitive to the 613 serum (Crooks et al.,
2015). As also coincidentally occurred with the 347 rabbit, serum 742
breadth might have been limited by the fact that this rabbit died before
boosting was complete.
2.6. EBects of modifying VLP production and immunization strategies
To try to alleviate our VLP production challenges, in Study 2 (out-
lined in Fig. S2), VLPs were prepared in 293 freestyle (293 F) cells and
were used to immunize 5 groups of 4 rabbits to attempt to investigate
different immunization variables. First, we investigated the effects of
two different adjuvants (AS01⁠B and Adjuplex in groups 2 A and 2B, re-
spectively) on nAb induction to parent VLPs. Second, we investigated
the effects of administering plasmids encoding the same Env, Gag and
Rev used to make N362Q VLPs in prime-boost (group 2D) or co-admin-
istration formats (group 2E), as compared to a N362Q VLP only control
group (group 2 C). A comparison of groups 2 A and 2 C should allow
us to determine the effects of removing the N362 glycan. Groups 2C-2E
were later boosted with parent VLPs mixed with the N362Q VLP at day
190. Due to some evidence of nAb development (see below), groups 2D
and 2E were boosted again at day 267.
Day 190 sera from study 2 were analyzed in Fig. S3. To facili-
tate comparisons of responses to VLPs produced in 293 T cells, sera
from Study 1
Fig. 8. N463 glycan-dependent sera target the glycan core. Rabbit vaccine sera and mAb controls PG9 and VRC01 were evaluated for neutralization of the N362 index virus prepared in
the presence or absence of kifunensine to inhibit high mannose glycan trimming.
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Fig. 9. Fine mapping of serum 742. A) Serum 742 was assayed for cross-neutralization of various clade B N197 knockout mutants. Global changes in sensitivity of these mutants was
ruled out previously (Crooks et al., 2015), suggesting that any serum cross-neutralization observed is genuine and is not due to overt changes in folding related to the mutation. B). Effect
of JR-FL glycan fence modiUcations on sensitivity to serum 742.
and groups A and B are included. We mined this data by Mann-Whitney
analyses of paired groups (Fig. S4). To investigate the effect producer
cell line, we compared Study 1 and group 2 C (both used N362Q VLPs
in AS01⁠B) and groups [A and B] (combined) and 2 A (both used par-
ent VLPs formulated in AS01⁠B). One caveat, however, is that the precise
regime in Study 2 and previous studies differ somewhat (Fig. 2 and S2
and ref (Crooks et al., 2015)). Nevertheless, we hoped to document any
significant leads by analyzing samples in parallel using the same assays.
By similar reasoning, we compared other groups to evaluate other vari-
ables (see Fig. S4).
Gp120 titers were not significantly different between most group
pairings (Fig. S4). A direct comparison of groups 2 A and 2B that re-
ceived identical regimens aside from the adjuvant revealed no signifi-
cant difference. However, a comparison of group 2 A and all the other
Study 2 sera reached significance (P=0.0157 in Fig. S4). A caveat, how-
ever, is that these regimens differed by more than just the adjuvant.
Bald VLP titers were significantly higher in rabbits immunized with
293 F VLPs than those produced in 293 T cells (P=0.0286 and 0.004 in
Fig. S4). We return to this point later below. The higher bald-VLP titers
in group 2B were not quite significantly higher than those in group 2 A.
However, they were significant when group 2B was compared to the
other Study 2 sera (P=0.0074). This latter comparison carries weight,
because the differences in Env between groups are largely irrelevant
for inducing bald-VLP titers and all rabbits received identical doses of
VLPs that are known to induce bald VLP titers. Indeed, there were no
significant differences in bald VLP titers between the other Study 2
groups. This was true even for group 2D (DNA prime, VLP boost group)
that did not receive protein immunogen until the 4th shot and bald
VLP titers were measured after only one additional protein boost (Fig.
S2). Taken together, 293 F production dramatically increases bald VLP
binding titers and there is a possible slight improvement in binding re-
sponses with Adjuplex.
We next compared the neutralizing responses of the same groups.
Tier 1 responses did not differ significantly between groups (Fig. S4).
However, there was significant individual variation. Although the titers
in group 2E appeared to be the lowest, they were not significantly dif-
ferent from those in groups 2D and 2E. Tier 2 nAbs, where measureable,
were not different in most cases, except that N362Q titers were signif-
icantly higher in Study 1 sera than in group 2 C (where no nAbs were
detected). This trend was also true for parent virus neutralization, but
did not reach significance in part due to the lack of response in rab-
bit 743. In fact, tier 2 nAb responses were poor throughout Study 2.
Only 2 out of 20 Study 2 animals exhibited measurable ID50s. Serum
773 neutralized N362Q and parent viruses and serum 776 neutralized
only the N362Q virus. It is perhaps no coincidence that both neu
tralizing Study 2 sera came from groups D and E (see Fig. 2) that, unlike
the other groups, received plasmid DNA as well as VLP immunogens.
Serum IgG from the 773 and 776 rabbits bound to native SOS
E168K+N362Q trimer (Fig 5A, upper panel). However, non-neutraliz-
ing IgG from rabbit 770 did not (Fig. S3). Similar patterns were ob-
served using SOS E168K trimers, except that serum 776 failed to bind ef-
fectively (Fig. 5A, middle panel), consistent with its lack of parent virus
neutralization (Fig. S3). These sera also recognized D368-independent
epitopes (Fig. 5A, lower panel).
The data shown in Fig. S3 used Study 2 sera taken 2 weeks after the
day 90 boost (Fig. S2). Due to the nAbs detected in rabbits 773 and 776,
groups 2D and 2E were boosted once more with a mixture of parent and
N362Q VLPs. However, improved nAbs titers did not develop in rabbits
773 and 776 (not shown) and nAbs did not develop in the other rabbits.
The general failure of Study 2 suggests that 293F-produced VLPs, un-
like those produced in 293 T cells are ineffective at inducing nAbs. We
attempted to understand this result so that similar problems might be
avoided in the future. In Studies 1 and 2, VLP doses were prepared from
the same volumes of supernatants derived from 293 T or 293 F transfec-
tions. Although these cell lines derive from the same origin, their VLPs
products exhibited qualitative differences. 293 F VLP pellets were no-
ticeably larger than those produced by 293 T cells (Fig. S5A). Further-
more, trimer staining was less intense for undigested 293 F VLPs com-
pared to 293 T VLPs (Fig. S5B, lanes 1 6). However, upon protease di-
gestion prior to VLP lysis and BN-PAGE, the trimer staining was com-
parable (Fig. S5B, lanes 7 12). VLPs coated on ELISA wells at 20x con-
centration and measured for antigenicity revealed significantly weaker
mAb binding to 293 F VLPs (Fig. S5C). However, mAb 2F5 bound equiv-
alently probably due to its previously reported ability to cross-react with
lipid, as indicated by its ability to recognize bald VLPs (Tong et al.,
2012). Finally, pseudovirus produced in 293 F cells was very poorly in-
fectious compared to the cognate 293 T virus (Fig. S2D).
3. Discussion
Here, we set out with two objectives. First, we sought to improve
the frequency of VLP-induced nAb responses by increasing access to
the CD4bs. Second, we attempted to increase the cross-reactivity of ini-
tial autologous nAbs using modiUed VLP boosts. Regarding the Urst
goal, we removed the N362 glycan to try to minimize potential clashes
with nascent antibodies that overlap the CD4bs and thereby relax road-
blocks to nAb induction (Bonsignori et al., 2016; Kong et al., 2016;
Li et al., 2008; McGuire et al., 2013). Tier 2 isolates frequently lack
some glycans that are present on most
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other circulating strains (McCoy et al., 2016). Glycan holes are also
a feature of strains associated with nAb breadth in natural infection
(Moore et al., 2015; van den Kerkhof et al., 2013). Modestly glycan-de-
pleted tier 2 viruses can also transmit infection, perhaps because they
function well in settings where nAb resistance is unimportant (Chohan
et al., 2005; Derdeyn et al., 2004; Ping et al., 2013). Here we found that
enlarging the CD4bs glycan hole led to the induction of tier 2 nAbs in
4 out of 4 (100%) of animals in Study 1 (Fig. 3). However, perhaps in-
evitably, the bigger hole exposed additional antibody targets.
In Fig. 10, we modeled the targets of the sera of the present and pre-
vious studies. All our mapped sera appeared to target epitopes close to
the CD4bs. Serum 742 targeted an N197 glycan-sensitive epitope ("epi-
tope cluster 1" in Fig. 10) that was akin those of sera 347 and 613
(Crooks et al., 2015). Although the vaccine group sizes (n=4) are small,
it is perhaps no coincidence that 1/4 rabbits in each group targeted this
epitope (i.e., 25%; 3 out of 12 rabbits in total). The frequency of re-
sponses to this site was apparently not improved by N362 glycan re-
moval. Indeed, the 742 serum depends heavily on the glycan hole at po-
sition 197, but is impartial to the additional space provided by the N362
glycan vacancy (Figs. 1E and 9B). Like the 347 and 613 sera (Crooks et
al., 2015), serum 742 cross-neutralized N197 glycan knockout mutants
of both the JR-CSF and ADA strains. This may reVect the limited IgG
repertoire solutions able to take advantage of the N197 glycan hole. The
fact that the cross-neutralized N197 glycan-deUcient viruses retain a tier
2 phenotype provides hope that inducing tier 2 breadth may be feasible.
Our attempt to improve the frequency of nAb responses to the N197
glycan hole by removing the adjacent N362 glycan had the unintended
consequence of leading to responses to other, less conserved sites. Sera
740 and 741 were dependent on the N463 glycan - a fence glycan in
the V5 loop (modeled as "epitope cluster 2" in Fig. 10). The V5 loop has
in fact been frequently reported as a target of low titer tier 2 vaccine
sera (Law et al., 2007; Leaman et al., 2015; Narayan et al., 2013). The
N463 glycan is present in only 20.3% of circulating viruses (analyzed
from 4265 sequences in www.hiv.lanl.gov). Other poorly conserved gly-
cans appear at adjacent positions in the V5 loop that serve to limit ac-
cess to CD4bs-speciUc nAbs by introducing steric clashes. In the case of
VRC01 class bnAbs, V5 glycan-light chain clashes are a major mecha-
nism of resistance (Huang et al., 2016). Although these sera also appear
to clash with complex glycan head groups (Fig. 8), they were distinct in
that they required the N463 glycan rather than avoided it.
Fig. 10. Epitope footprints of neutralizing sera. The model shown in Fig. 1C was repro-
duced with putative epitope footprint clusters for trimer VLP vaccine sera of the current
study and two potently neutralizing rabbit sera 613 and 347 from our previous study
(Crooks et al., 2015). Serum from animal 773 was not mapped because the titer was too
low. Footprint sizes are intended as a guide only and may be larger than shown, based on
VRC01 docking in Fig. 1B.
This is not necessarily at odds with the growing evidence that glycan
holes are preferred nAb targets (Crooks et al., 2015; McCoy et al., 2016).
Despite the apparent N463-dependency, these sera initially targeted the
N362 glycan hole. As mentioned above, we can not rule out the possibil-
ity that the sera recognize a structure created by the glycan rather than
the glycan itself. Fence glycans N362 and N463 are spatially close and
it is logical that removal of the former might expose epitopes that im-
pinge somewhat on the latter (Fig. 10), especially given that CD4bs bn-
Abs appear to be unable to completely avoid making some glycan con-
tacts (Stewart-Jones et al., 2016). The same is also true for certain au-
tologous nAbs in natural infection (Wibmer et al., 2016). The 743 and
776 sera also targeted N362 glycan hole. However, unlike the 740 and
741 sera, they did not gain an ability to navigate the N362 glycan upon
boosting. As a result, we classiUed these sera as N362Q sensitive and
did not attempt to map them further (epitope cluster 3). We note how-
ever the likely overlap between clusters 2 and 3 in Fig. 10. The low titer
of the N362Q-insensitive serum of rabbit 773 precluded any attempt at
mapping (Fig. 10).
Despite the N463 glycan-dependency, the 740 serum incompletely
neutralized an N463 glycan-lacking JR-FL mutant (Fig. 7B) suggesting
that it may contact the underlying protein. Given V5 sequence variabil-
ity, it is perhaps not surprising that the 740 and 741 sera did not neu-
tralize other strains that carry the N463 glycan (Fig. 7D). Overall, the
apparent frequent targeting of this site by vaccine nAbs suggests that it
is relatively exposed and may be used by the virus to attract strain-spe-
ciUc responses that are easy to escape (Bradley et al., 2016; Wibmer et
al., 2016) making it a poor target for any attempt to evolve nAb breadth.
In addition to exposing new nAb epitopes, our data hint that N362
glycan removal may have had other subtle effects. Unlike our previous
study, our new sera targeted epitopes that were largely contained within
gp120 monomers (Fig. 5B). Furthermore, serum 742, unlike the 613 and
347 sera, was partially sensitive to the D368R mutation in the CD4 bind-
ing loop. However, it is important to point out that the small numbers
of responders to each epitope preclude any Urm statement regarding the
consistency of these Undings. Overall, our data suggest that improving
the frequency of nAbs to the N197 glycan hole will require a different
strategy. Rather than improving lateral access to this site by N362 gly-
can removal, one approach may be to minimize glycan size at priming
to eliminate any potential glycan clashes, perhaps by preparing trimer
VLPs in GnTI- cells (Binley et al., 2010).
Our second major goal was to improve nAbs cross-reactivity. In both
vaccination and natural infection settings, initial nAbs are invariably
highly strain-speciUc and so there may be little hope of eliciting bnAbs
directly. If so, it might be possible to evolve breadth from initial autol-
ogous nAbs using modiUed boosts to change nAb speciUcity. A recent
study showed that multi-strain SOSIP gp140 trimer vaccines induce very
limited breadth against strains not included in the regimen (Klasse et
al., 2016). Thus, it may be important to design vaccines that promote
nAb development to conserved targets. Natural infection studies pro-
vide relevant paradigms of the events leading up to bnAb development
(Derdeyn et al., 2014; Doria-Rose et al., 2014; Gao et al., 2014; Liao et
al., 2013; Moore et al., 2012; Murphy et al., 2013; Ping et al., 2013). In
some cases, breadth develops after the virus escapes autologous nAbs,
as a newly introduced glycan creates a new broad site of vulnerability
(Derdeyn et al., 2014; Moore et al., 2012; Ping et al., 2013; Wibmer et
al., 2013). In some cases, bnAbs avoid glycan clashes by altering their
angle of approach (Garces et al., 2015; Tran et al., 2014). In other cases,
rather by necessity rather than preference, bnAbs acquire glycans con-
tacts (Stewart-Jones et al., 2016; Zhou et al., 2015, 2013). This contrasts
with other viruses such as inVuenza where, despite quite high glycan
content (albeit not as high as for HIV Env), nAbs rarely contact glycans
(Pancera et al., 2014; Stewart-Jones et al., 2016).
In a vaccine setting, breadth may be improved simply by addi-
tional boosts, as occurred for rabbit 613, where boosting expanded
nAb breadth from neutralizing 3 of 18 (like the 347 and 742 sera)
to 9 of 18 clade B N197 glycan-lacking viruses (Crooks et al., 2015).
However, the natural infection paradigms above suggest that targeted
boosting strategies might be impor
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tant. The need to broaden cross-reactivity using boosts is underlined
by our sera's preference for the precise immunogen presentation even
within the vaccine strain. For example, in Fig. 4, serum 742 preferen-
tially neutralizes SOS mutant viruses over their WT counterparts, de-
spite the negligible effect of this mutation on trimer conformation. The
4th N362Q VLP shot of this rabbit promoted an overlap of the N362
glycan hole, suggesting that boosting can narrow as well as broaden
cross-reactivity.
The acute effects of marginal antigenic differences on antibody tar-
geting we discussed above together the inability of multi-strain prime
boost approaches to induce breadth, suggest that expanding nAb
cross-reactivity may at least initially require a subtler, rationally de-
signed boosting approach. One approach is to select prospective boosts
based on their recognition by interim sera. Unlike the multi-strain
strategies, this "aWnity drop" concept (Steichen et al., 2016) should en-
sure that boosts will reactivate pre-existing clones. Incremental changes
induced by this approach might lead nAbs on a rational path to breadth.
In keeping with the aWnity drop concept, Study 1 rabbits were
boosted with parent VLPs mixed with the index N362Q VLPs. A kinetic
analysis of rabbits 740 and 741 (Fig. 4) suggested that cross-reactiv-
ity with JR-FL variants may have been promoted by these boosts, espe-
cially in rabbit 740. However, as mentioned elsewhere, VLP production
challenges precluded the larger rabbits that would be needed to identify
consistent patterns.
Given its conserved epitope, had rabbit 742 survived, the aWnity
drop approach might have been more valuable. In this case, poten-
tial boosts could be designed to i) increase cross-reactivity with N197
knockout mutants of other Env strains and ii) navigate the N197 glycan.
Clearly, the value of these ideas need to be determined experimentally,
with the only stipulation that boosts are recognized preceding sera. A
complete strategy may also require an initial sensitive prime (e.g. GnTI-
VLPs) to promote consistent nAb responses in all vaccinees.
Glycan holes are likely to remain a focus of vaccine development
in the forseeable future. However, several factors need to be consid-
ered. One is that they should target conserved sites where a glycan is
normally present in most strains. Thus, N197 hole (98.7% conserved)
is preferable to one at position 463 (20.3% conserved). It may also be
useful to plug holes at highly variable holes with glycan to prevent
unwanted responses. However, it may be no coincidence that the gly-
can holes targeted by autologous vaccine nAbs reported so far usually
occur at reasonably conserved positions, for example N197 (98.7%),
N230 (32.7%) N241 (97%), N289 (69.4%), N611 (98.4%) (Crooks et al.,
2015; McCoy et al., 2016). Glycan absences at these sites appear to have
greater consequences than those at more variable sites. A second factor
is antigenic context. For example, while JR-FL strain VLPs induced nAbs
to the 197 glycan hole, a JR-FL gp160 DNA prime, protein boost regi-
men targeted the N230 glycan hole (Crooks et al., 2015), perhaps due to
the subtle antigenic differences between these antigens. A third factor is
that when Env glycans are absent, neighboring glycans may reposition
and/or differentiate into larger multi-branched glycans that may inter-
lock in new ways to partially occupy the vacated space, thereby compli-
cating their ability to induce nAbs (Behrens et al., 2016; Stewart-Jones
et al., 2016; Zhou et al., submitted for publication).
Previous studies showed that removing the N276 glycan improves
VRC01 class germline priming (Jardine et al., 2013, 2016; McGuire et
al., 2013). However, a high sensitivity to the mature VRC01 bnAb (Fig.
1D) led us to choose the N362Q mutant here. In a study by another
group, removing four CD4bs fence glycans from BG505 SOSIP trimers
(Zhou et al., submitted for publication) led to dramatically improved
(>1000 fold) neutralizing ID50s to the CD4bs of the glycan-depleted
parent strain that could, to some extent, neutralize other isolates if the
fence was similarly dismantled. However, as in our study, a drawback is
that these nAbs do not effectively navigate the intact glycans of the par-
ent virus. For these reasons, the subtler approaches we describe above
may be more effective.
The need for high VLPs doses raises questions about their prospects
for process development. Our current VLP platform is largely intended
for proof of concept. Over the last decade, we have optimized plas-
mid combinations
to improve trimer output by at least 10-fold per unit culture (Crooks et
al., 2007, 2015; Tong et al., 2014). Our investigation of 293 F VLPs was
intended to eliminate this production bottleneck, but was unsuccessful,
apparently due to contaminating material, possibly vesicles. An alter-
native platform to investigate membrane trimers that we are now in-
vestigating is to extract membrane trimers, then reconstitute them into
liposomes or nanodiscs (Frauenfeld et al., 2016; Nakatani-Webster et
al., 2015). In the meantime, the consistently positive nAb responses to
N362Q mutant VLPs observed here should facilitate immediate efforts
to formally re-evaluate the VLP dose required to induce nAbs, which
could temporarily alleviate our current challenges in evaluating con-
cepts with full concurrent controls (current doses are high in part to err
on the side of caution).
Overall, our study provides some encouraging leads for vaccine de-
velopment. The frequency of autologous tier 2 nAbs appeared to be im-
proved by enlarging the CD4bs glycan hole. Targeted glycan holes at
conserved positions might be most effective if used as part of a com-
posite strategy with other glycan modiUcations and heterologous boosts
selected by the aWnity drop concept. A continued commitment to itera-
tive, rational improvements may in future bring us closer to our goal of
inducing tier 2 breadth.
4. Materials and methods
4.1. Anti-HIV-1 Env monoclonal antibodies
Monoclonal antibodies (mAbs) were obtained from their producers,
the NIH AIDS reagent repository, or from commercial suppliers. Infor-
mation on these mAbs can be found at the web link: (www.hiv.lanl.gov).
Our mAb panel included the following (originators given in parenthe-
ses): 2G12 (Katinger), directed to a unique glycan-dependent epitope of
gp120 (Scanlan et al., 2002); 39 F and CO11 (J. Robinson), directed to
the gp120 V3 loop (Crooks et al., 2005; Tong et al., 2012, 2014); b12
(Burton), VRC01 and VRC13 (Mascola), 8ANC131 (Nussenzweig), HJ16
(Lanzavecchia), 15e (J.Robinson), directed to epitopes that overlap the
CD4bs (Scheid et al., 2011; Tong et al., 2012; Wu et al., 2010; Zhou
et al., 2015); PGT121 (Burton) directed to epitopes involving the base
of the V3 loop of gp120 and the N332 glycan (Walker et al., 2011);
PG9 and PG16 (Burton); directed to quaternary, glycan-dependent epi-
topes that involve the V2 loop (Doria-Rose et al., 2014; Walker et al.,
2009); 7B2 and 2.2B (J. Robinson), directed to the gp41 cluster I and
II epitopes, respectively (Moore et al., 2012); 4E10 and 2F5 (Katinger),
directed to the gp41 membrane-proximal ectodomain region (MPER)
(Huang et al., 2012).
4.2. Recombinant gp120 monomer, gp41, soluble CD4 and CD4-IgG
Recombinant monomeric JR-FL gp120 and mutants thereof were
produced in 293 T cells and puriUed from supernatants over Galanthus
nivalis agarose. Soluble CD4 (sCD4) consisting of its 4 outer domains
was a gift from Progenics Pharmaceuticals (Tarrytown, NY).
4.3. Plasmids and mutagenesis
Plasmid pCAGGS was used to express JR-FL gp160 CT on VLP sur-
faces (Moore et al., 2006). Gp160 CT is truncated at amino acid 709,
leaving a 3 amino acid gp41 cytoplasmic tail. This increases native
trimer expression and produces pseudoviruses with similar neutraliza-
tion sensitivity proUles compared to their full-length gp160 counter-
parts (Crooks et al., 2005). The use of the JR-FL Env strain has sev-
eral advantages, including efUcient expression and gp120/gp41 pro-
cessing (Crooks et al., 2005; Moore et al., 2006). Mutants were gen-
erated by Quikchange (Agilent Technologies) and were numbered per
the HXB2 reference strain (Binley et al., 2008). "SOS" mutations (A501C
and T506C) introduce an intermolecular disulUde bond between gp120
and gp41 (Binley et al., 2000). The E168K mutation knocks in the
broadly neutralizing PG epitopes that are normally absent in the
JR-FL isolate and increases trimer expression (Tong et al., 2012). Mu
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tants D197N, N276A, N362Q, N386A, N392Q and N463Q knock-in or
knockout glycans that line the CD4bs. The A328G mutation dramati-
cally enhances neutralization sensitivity, otherwise known as "global"
sensitivity (Tong et al., 2012). The D368R mutation abrogates CD4
binding capability.
Plasmids expressing gp160 from other strains were obtained from
the NIH AIDS Reagent Repository. Mutant versions of these sequences
in which the N197 glycan is eliminated were produced. Another set of
plasmids encoded a series of domain-exchanged hybrid gp160s using
sequences from the JR-FL and JR-CSF isolates (Narayan et al., 2013).
Plasmids used to make VLPs included pMV-ERV Gag (expresses endoge-
nous murine leukemia virus Gag under the control of a CMV promoter
(Bashratyan et al., in press) and pMV-Rev 0932 (expresses codon-opti-
mized HIV-1 Rev under the control of a CMV promoter).
4.4. VLP production
VLPs were produced by co-transfecting 293 T cells with an Env-ex-
pressing plasmid (typically pCAGGS JR-FL gp160 CT SOS E168K and
mutants thereof and, in select cases, p0001 JR-CSF gp160 CT SOS),
pMV-ERV Gag and pMV-0932, using polyethyleneimine (PEI Max), as
described previously (Tong et al., 2012). Two days later, supernatants
were collected, precleared by low speed centrifugation, Ultered and pel-
leted at 50,000 g in a Sorvall SS34 rotor. To remove residual medium,
VLP pellets were diluted with 1 ml of PBS, then re-centrifuged at
15,000 rpm and resuspended in PBS at 1000 x the original concentra-
tion. VLPs were referred to as WT-VLPs or SOS-VLPs, depending on the
form of Env displayed on their surfaces or as bald-VLPs, bearing no
Env, produced by transfecting pNL4-3. Luc. R-E- alone (Crooks et al.,
2007). "Trimer-VLPs" were made by digestion using a cocktail of pro-
teases including proteinase K, subtilisin, trypsin and chymotrypsin, as
previously described (Crooks et al., 2011; Tong et al., 2012). VLPs were
inactivated using aldrithiol (AT-2) (Crooks et al., 2007). VLPs were also
made in 293 Expi freestyle cells. Following transfection, cells were har-
vested when they reached ~60% viability, at which point, cells were
pre-cleared by low speed centrifugation. The supernatant was then Ul-
tered with 1.2 m MWCO dead-end Ulter and concentrated by tangen-
tial Vow Ultration (100 kDa Ulter) to approximately 100-200x the initial
volume.
4.5. Animal immunizations
4.5.1. Species
New Zealand white rabbits were housed and immunized at the
Pocono Rabbit Farm (Canadensis, PA) a site that has been approved by
the Association for Assessment and Accreditation of Laboratory Animal
Care (AALAC). All animals were fed and handled in strict accordance
with the recommendations of the NIH Guide for the Care and Use of Lab-
oratory Animals and the Animal Welfare Act.
All immunization protocols were approved (protocol PRF2A) by the
Explora Biolabs Animal Care and Use Committee (IACUC). Explora Bi-
olabs animal welfare assurance (AWA) number is A4487-01. Pocono
Rabbit Farm is approved for rabbit and guinea pig immunizations by
the Association for Assessment and Accreditation of Laboratory Animal
Care (AALAC). The AWA number Pocono Rabbit Farm is A3886-01. For
all immunization and bleed protocols, pain and distress was slight and
momentary and did not affect animal health. Discomfort and injury to
animals was limited to that which is unavoidable in the conduct of sci-
entifically valuable research. Analgesics, anesthetics, and tranquilizing
drugs were used as necessary by veterinary staX. After the completion
of all immunizations and bleeds, rabbits were euthanized by injection
of an overdose of anesthesia per NIH guidelines. Ketamine and xyalzine
were administered intramuscularly at 35 mg/kg and 5 mg/kg, respec-
tively, followed by exsanguination via cardiac puncture.
Procedures for adverse reactions to immunization followed estab-
lished practices that include measures for dealing with unexpected
outcomes. For example, if an animal had an adverse reaction at the
injection site, depending
on the severity, the response would be either i) none in the case of mild
reactions, ii) anesthetic in the case of medium reaction, and iii) veteri-
nary staX would be brought in for severe cases, in which it may be nec-
essary to euthanize via an overdose of pentobarbital (100 mg/kg i.v.),
per guidelines established in 1993 by the American Veterinary Medical
Association Panel on Euthanasia. However, in this study, reactions to
all procedures were only mild and no animals were euthanized over the
course of immunizations and bleeds. Two rabbits, however (742 and
743 in Study 1) died unexpectedly, but this was unrelated to the immu-
nization and bleed procedures.
4.5.2. Immunizations
Six groups of 4 female rabbits were immunized in two studies, as
outlined in Fig. 2 and S2. In all groups, each dose of VLPs was harvested
from a total of 1 L transfection supernatant for initial shots and 500 ml
for boosts. Standard serum volumes were drawn on the day of each im-
munization and two weeks thereafter.
4.5.3. Study 1
One group of 4 rabbits were immunized intramuscularly with VLPs
formulated in AS01⁠B (Glaxo SmithKline, consisting of liposomes contain-
ing deacylated monophosphoryl lipid A and QS-21). VLP doses were
determined by documenting their relative antigenicity compared with
JR-FL gp120 by ELISA, using various mAbs, as we described previously
(Tong et al., 2014). As depicted in Fig. 2, initial shots consisted of JR-FL
SOS N362Q trimer VLPs, but later shots included mixtures of VLPs.
4.5.4. Study 2
Five groups of 4 rabbits were immunized to try to evaluate adju-
vant and plasmid DNA immunizations. Groups A and B were immu-
nized intramuscularly with JR-FL SOS E168K parent trimer VLPs for-
mulated in either AS01⁠B or Adjuplex, respectively. Adjuplex was ob-
tained from Advanced BioAdjuvants, and consists of puriUed lecithin
and carbomer homopolymer. Group C was a protein only immunogen
control group for DNA immunization Groups D and E. Group C rabbits
received 3 shots of JR-FL SOS N362Q trimer VLPs formulated in AS01⁠B,
followed by boost containing the same index immunogen mixed with
JR-FL SOS parent trimer VLPs also formulated in AS01⁠B. Group D rabbits
received 3 shots of plasmid DNA, consisting of 227 g pCAGGS JR-FL
SOS E168K+N362Q, 227 g pMV-ERV Gag and 46 g of pMV-Rev 0932
that was administered intramuscularly without adjuvant using a BTX
ECM 830 electroporation device. Protein boosts consisted of VLPs mixed
with AS01⁠B. Group E rabbits received concomitant priming immuniza-
tions of plasmid DNA (as above) and VLPs. These immunogens were ad-
ministered separately, one in each hind leg. Rabbits were later boosted
with trimer VLP mixtures in AS01⁠B, as indicated in Fig. S2.
4.6. Reference sera and plasmas
Reference controls included a pooled serum generated from six rab-
bits that were immunized with monomeric gp120 in AS01⁠B, as de-
scribed previously (Tong et al., 2014). We also included rabbit sera from
our previous study (Crooks et al., 2015). HIV-1-infected donor plasma
1702 and uninfected control plasma 210 were also described previously
(Binley et al., 2008; Tong et al., 2014).
4.7. ELISAs using recombinant gp120 and VLPs
ELISAs were used to measure serum binding to various antigens
and were also used to determine their speciUcities (Tong et al., 2012,
2014, 2013). BrieVy, Immulon II plates were coated with 20x concen-
trated VLPs, recombinant gp120 at 5 g/ml overnight at 4 C. Follow-
ing a PBS wash and blocking, sera were titrated against each antigen
in blocking buXer. Species-speciUc alkaline phosphatase anti-Fc con-
jugates (Accurate, Westbury, NY) and SigmaFAST p-nitrophenyl phos-
phate tablets (Sigma) were then used to
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detect binding. Plates were read at 405 nm. Titers are taken when ELISA
signals exhibited an optical density of 0.5 (approximately 3x back-
ground).
4.8. Blue Native PAGE (BN-PAGE)-Western blots
Blue native PAGE (BN-PAGE) was performed as described previously
(Crooks et al., 2007, 2005; Moore et al., 2006). BrieVy, VLPs were sol-
ubilized in 0.12% Triton X-100 in 1 mM EDTA. An equal volume of
2x sample buXer (100 mM morpholinepropanesulfonic acid (MOPS),
100 mM Tris HCl, pH 7.7, 40% glycerol, and 0.1% Coomassie blue)
was added. Samples were then loaded onto a 4 12% Bis-Tris NuPAGE
gel (Invitrogen) and separated at 4 C for 3 h at 100 V. The gel was
then blotted onto polyvinylidene diVuoride membrane, destained, im-
mersed in blocking buXer (4% nonfat milk in PBS) and probed with an
anti-gp120 cocktail (mAb b12 and 39 F at 1 g/ml) and/or an anti-gp41
cocktail (mAb 2F5, 4E10, 7B2, 2.2B at 1 g/ml). Blots were then probed
by an anti-human Fc alkaline phosphatase conjugate (Accurate Chemi-
cals) and developed using SigmaFast BCIP/NBT substrate (Sigma).
BN-PAGE shift assays were used to measure the ability of antibod-
ies to bind and deplete the unliganded trimer (Crooks et al., 2007, 2005;
Moore et al., 2006; Tong et al., 2012). VLPs were incubated with mAb
or protein A-puriUed serum IgG for 1 h at 37 C, then washed with PBS
and resolved by BN-PAGE-Western blot, as above.
4.9. Neutralization assays
Heat-inactivated sera were analyzed for neutralization of various
pseudoviruses produced by co-transfecting either 293 T cells with an
Env plasmid and pNL4-3. Luc. R-E- (CF2 assays). Data is representative
of at least 3 repeat assays performed in duplicate.
4.9.1. Neutralization assays using CF2 cell targets
Neutralization assays using canine CF2 cells expressing CD4 and
CCR5 receptors (CF2Th. CD4. CCR5) have been described previously
(Crooks et al., 2005). BrieVy, virus was incubated with graded dilutions
of mAb or serum for 1 h at 37 C. The mixture was then added to CF2
cells, spinoculated at 300 x g for 15 min, incubated at 37 C. For WT
viruses, cells were cultured for a further 3 days, then luciferase activ-
ity was measured. For SOS mutant viruses, after 2 h, the medium was
removed and infection was activated by adding 5 mM DTT for 5 min,
followed by a wash (Crooks et al., 2005) and culturing for a further 3
days, after which luciferase activity was measured.
4.9.2. Monomeric gp120 interference of neutralization
In modiUed neutralization assays, Uxed concentrations (~1 g/ml)
of recombinant JR-FL gp120 monomer trimer carrying N362Q and
D386R mutations, was added to the virus-antibody mixture to test for
its ability to interfere with the neutralizing activity in the test serum.
4.10. Statistical analyses
Immunization groups were compared using Mann-Whitney tests. For
neutralization titer comparisons, undetectable titers were given an arbi-
trary titer of 4 for calculations.
4.11. Molecular modeling
The recently reported full-length JR-FL Env structure of (PDB: 5FUU)
(Lee et al., 2016) was used to generate a visual model for the distri-
bution of glycans on the native spike. First, atomic clashes present in
the 5FUU structure were relieved and missing side-chains rebuilt by
executing 1000 symmetric ROSETTA-Uxbb simulations, selecting the
lowest scoring model, and then running a constrained ROSETTA-re-
lax simulation. Each N-linked gly
cosylation motif was decorated with a Man⁠8GlcNAc⁠2 glycan. The gly-
can at position N637 in gp41 is absent, per evidence that one or other
glycans at N625 and N637 remain unoccupied (Go et al., 2008). For
any overlapping sequons, for example those at N188 and 189, only the
Urst sequon is occupied. GlycanRelax (Pancera et al., 2010) was used to
approximate the conformational behavior of glycans in a glycoprotein
context. For each model, 10 separate GlycanRelax trajectories of 10,000
cycles of MonteCarlo trials were carried out. Each gp120 glycan could
move independently throughout the GlycanRelax minimization. A sin-
gle low energy model was chosen and Ugures were generated in PyMOL
Molecular Modeling Software (Version 1.5.0.4 Schr dinger, LLC).
4.12. Ethics statement
The archived adult human plasmas used in this study have previ-
ously been described (Binley et al., 2008; Tong et al., 2014). All donors
provided written consent for the use of these samples. Institutional Re-
view Board (IRB) approval for this project was obtained through the San
Diego Biomedical Research Institute IRB Committee (approval number:
IRB-14-04-JB; Federal Wide Assurance number: 00021327).
All immunization protocols for rabbits were approved (protocol
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dance with the recommendations of the NIH Guide for the Care and
Use of Laboratory Animals, the Animal Welfare Act and Regulations and
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